Literature DB >> 22543846

Late-life depression as a risk factor for mild cognitive impairment or Alzheimer's disease in 30 US Alzheimer's disease centers.

Kyle Steenland1, Conny Karnes, Ryan Seals, Claudine Carnevale, Adriana Hermida, Allan Levey.   

Abstract

Identification of potentially modifiable risk factors for cognitive deterioration is important. We conducted a prospective study of 5,607 subjects with normal cognition and 2,500 subjects with mild cognitive impairment (MCI) at 30 Alzheimer's Disease Centers in the Unites States between 2005 and 2011. Cox regression was used to determine whether depression predicted transition from normal to MCI, or MCI to Alzheimer's disease (AD). Over an average of 3.3 visits, 15% of normal subjects transitioned to MCI (62/1000 per year), while 38% of MCI subjects transitioned to AD (146/1000 per year). At baseline, 22% of participants had recent (within the last two years) depression defined by clinician judgment; 9% and 17% were depressed using the Geriatric Depression Scale (GDS score ≥5) and the Neuropsychiatric Inventory Questionnaire (NPI-Q), respectively. At baseline, depressed subjects performed significantly worse on cognitive tests. Those always depressed throughout follow-up had an increased risk for progression from normal to MCI (RR = 2.35; 95% CI 1.93-3.08) versus never depressed. Normal subjects, identified as depressed at first visit but subsequently improved, were found to have lower risk of progression (RR 1.40 (1.01-1.95)). The 'always depressed' had only a modest increased risk of progression from MCI to AD (RR = 1.21 (1.00-1.46). Results were similar using time-dependent variables for depression or when defining depression via the GDS or NPI-Q. We found no effect of earlier depression (>2 years past). The effect of recent depression did not differ by antidepressant treatment, APOE4 allele status, or type of MCI. In conclusion, late-life depression is a strong risk factor for normal subjects progressing to MCI.

Entities:  

Mesh:

Year:  2012        PMID: 22543846      PMCID: PMC3729228          DOI: 10.3233/JAD-2012-111922

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  41 in total

Review 1.  Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies.

Authors:  A Frazer
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

2.  The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging.

Authors:  R O Roberts; Y E Geda; D S Knopman; R H Cha; V S Pankratz; B F Boeve; E G Tangalos; R J Ivnik; W A Rocca; R C Petersen
Journal:  Neurology       Date:  2012-01-25       Impact factor: 9.910

3.  The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database.

Authors:  Duane L Beekly; Erin M Ramos; Gerald van Belle; Woodrow Deitrich; Amber D Clark; Mary E Jacka; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2004 Oct-Dec       Impact factor: 2.703

4.  Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study.

Authors:  Philippe H Robert; Claudine Berr; Magali Volteau; Christelle Bertogliati; Michel Benoit; M Sarazin; Sylvie Legrain; Bruno Dubois
Journal:  Clin Neurol Neurosurg       Date:  2006-03-29       Impact factor: 1.876

5.  The rate of conversion of mild cognitive impairment to dementia: predictive role of depression.

Authors:  T Gabryelewicz; M Styczynska; E Luczywek; A Barczak; A Pfeffer; W Androsiuk; M Chodakowska-Zebrowska; B Wasiak; B Peplonska; M Barcikowska
Journal:  Int J Geriatr Psychiatry       Date:  2007-06       Impact factor: 3.485

6.  Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis.

Authors:  Raymond L Ownby; Elizabeth Crocco; Amarilis Acevedo; Vineeth John; David Loewenstein
Journal:  Arch Gen Psychiatry       Date:  2006-05

7.  Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study.

Authors:  Yonas E Geda; David S Knopman; David A Mrazek; Gregory A Jicha; Glenn E Smith; Selamawit Negash; Bradley F Boeve; Robert J Ivnik; Ronald C Petersen; V Shane Pankratz; Walter A Rocca
Journal:  Arch Neurol       Date:  2006-03

8.  Predictors of progression from mild cognitive impairment to Alzheimer disease.

Authors:  K Palmer; A K Berger; R Monastero; B Winblad; L Bäckman; L Fratiglioni
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

9.  Chronic distress and incidence of mild cognitive impairment.

Authors:  R S Wilson; J A Schneider; P A Boyle; S E Arnold; Y Tang; D A Bennett
Journal:  Neurology       Date:  2007-06-12       Impact factor: 9.910

10.  Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study.

Authors:  Deborah E Barnes; George S Alexopoulos; Oscar L Lopez; Jeff D Williamson; Kristine Yaffe
Journal:  Arch Gen Psychiatry       Date:  2006-03
View more
  50 in total

1.  Clinicopathological correlates of depression in early Alzheimer's disease in the NACC.

Authors:  Sarah T McCutcheon; Dingfen Han; Juan Troncoso; Vassilis E Koliatsos; Marilyn Albert; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos
Journal:  Int J Geriatr Psychiatry       Date:  2016-02-14       Impact factor: 3.485

2.  Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients.

Authors:  Matthias Brendel; Oliver Pogarell; Guoming Xiong; Andreas Delker; Peter Bartenstein; Axel Rominger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-29       Impact factor: 9.236

Review 3.  The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link?

Authors:  Adriana P Hermida; William M McDonald; Kyle Steenland; Allan Levey
Journal:  Expert Rev Neurother       Date:  2012-11       Impact factor: 4.618

4.  The default mode network may be the key substrate of depressive symptom-related cognitive changes.

Authors:  Donald R Royall; Raymond F Palmer; Eric D Vidoni; Robyn A Honea
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

5.  Organic bases of late-life depression: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2013-01-25       Impact factor: 3.575

Review 6.  Cognitive rehabilitation therapies for Alzheimer's disease: a review of methods to improve treatment engagement and self-efficacy.

Authors:  Jimmy Choi; Elizabeth W Twamley
Journal:  Neuropsychol Rev       Date:  2013-02-12       Impact factor: 7.444

7.  Associations between depressive symptoms and memory deficits vary as a function of insulin-like growth factor (IGF-1) levels in healthy older adults.

Authors:  Feng Lin; Julie Suhr; Stephanie Diebold; Kathi L Heffner
Journal:  Psychoneuroendocrinology       Date:  2014-01-22       Impact factor: 4.905

8.  Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease.

Authors:  Nancy J Donovan; Rebecca E Amariglio; Amy S Zoller; Rebecca K Rudel; Teresa Gomez-Isla; Deborah Blacker; Bradley T Hyman; Joseph J Locascio; Keith A Johnson; Reisa A Sperling; Gad A Marshall; Dorene M Rentz
Journal:  Am J Geriatr Psychiatry       Date:  2014-02-26       Impact factor: 4.105

9.  Depressive symptoms in healthy apolipoprotein E ε4 carriers and noncarriers: a longitudinal study.

Authors:  Dona E C Locke; Amylou C Dueck; Cynthia M Stonnington; David S Knopman; Yonas E Geda; Richard J Caselli
Journal:  J Clin Psychiatry       Date:  2013-12       Impact factor: 4.384

Review 10.  Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications.

Authors:  Rita Khoury; George T Grossberg
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.